Stock Ratings / Health Care / RPID / dividends

HBIO (44) PRPO (38) EYPT (38) BNGO (36) ⌘ Pro Terminal →

Rapid Micro Biosystems Inc. (Class A) (RPID) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Does RPID pay a dividend and is it safe?

Rapid Micro Biosystems Inc. (Class A) (RPID) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$0.79 -1.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.79

Rapid Micro Biosystems Inc. (Class A) (RPID) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $39.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.79 (-0.44%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RPID)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY RPID SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.89-14.6% Next Q

Q2 (-2Q)

Grade C-$0.76+2.6% Next Q

Q3 (-1Q)

Grade C-$0.78+1.3% Next Q

Current

Grade D$0.79-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RPID Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RPID currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.09) and Max Pain ($0.83) forces dealer call-delta covering toward $5.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RPID• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RPID Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.6% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $32,763

Est. Year-10 Shareholder Yield: $590/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.7K

Yr 2

$14.3K

Yr 3

$16.1K

Yr 4

$18.1K

Yr 5

$20.4K

Yr 6

$22.9K

Yr 7

$25.8K

Yr 8

$29.1K

Yr 9

$32.8K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RPID)

✓Walkthrough of RPID's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RPID // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.08%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.78H $0.79L $0.70C $0.79VOL 201.6K

RES: $1.66SUP: $0.66SMA50: $1.09SMA200: $2.24

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RPID Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RPID Butterfly Map → + Track RPID →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +19.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RPID today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RPID. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RPID today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RPID)

Health Care Rank #420 of 1016 ⚔️ HBIO vs RPID Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RPID vs. HBIO, PRPO, EYPT, BNGO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapid Micro Biosystems Inc. (Class A) (RPID) ranks #420 by composite RQD confidence (47/100, grade D) and #777 by equity capitalization ($39.6M). Within this direct 5-issuer industry benchmark cohort, RPID leads on earnings valuation at N/A trailing P/E, while PRPO leads on capital efficiency and profitability with -7.9% ROIC and 44.2% gross margin. RPID currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RPID ACTIVE Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	Benchmark Subject
HBIO Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	/hbio-vs-rpid →
PRPO Precipio Inc.	D-	38/100	—	44.2%	-7.9%	+3.59%	$34.6M	/prpo-vs-rpid →
EYPT EyePoint Inc.	D-	38/100	—	—	-35.0%	+0.69%	$32.8M	/eypt-vs-rpid →
BNGO Bionano Genomics Inc.	D-	36/100	—	46.3%	-35.0%	-0.41%	$16.8M	/bngo-vs-rpid →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001380106

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapid Micro Biosystems Inc. (Class A) (RPID) reported GAAP revenue of $33.6M (+19.7% vs. FY2024 revenue of $28.1M , and +49.1% cumulative change since FY2023) , GAAP net income of -$47.1M, operating cash flow of -$31.1M, and free cash flow of -$31.9M (+29.9% YoY). On the balance sheet, RPID closed FY2025 with $74.9M in total assets against $18.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.6M	-$47.1M	-$31.1M	-$31.9M	$74.9M	$18.9M
FY2024 (FY)	2024-12-31	$28.1M	-$46.9M	-$44.2M	-$45.5M	$98.2M	$0
FY2023 (FY)	2023-12-31	$22.5M	-$52.5M	-$45.1M	-$45.1M	—	—

3. RPID Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RPID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Rapid Micro Biosystems Inc. (Class A) (NASDAQ: RPID) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $0.79 (-1.37% 1D, market cap $39.6M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RPID ranks #420 in composite RQD confidence.

How does RPID compare to HBIO and PRPO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RPID carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HBIO (Harvard Bioscience Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $40.1M) and PRPO (Precipio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -7.9%, cap $34.6M). Among the 5-stock peer group, RPID leads on earnings multiple (N/A) while PRPO leads on capital efficiency (-7.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RPID?

Per RPID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001380106), Rapid Micro Biosystems Inc. (Class A) generated $33.6M in revenue (+19.7% YoY), -$47.1M in net income, and -$31.9M in free cash flow against $74.9M in total assets and $18.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RPID trading relative to its 50-day, 200-day, and 52-week technical levels?

RPID last traded at $0.79 (-1.37% on volume of 192,150 shares), positioning the stock -27.52% below its 50-day simple moving average ($1.09) and -64.73% below its 200-day simple moving average ($2.24). Across its 52-week range of $0.70 to $4.94, RPID sits at the 2.1% percentile with a 14-day RSI of 27.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.89).

RPID Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does RPID pay a dividend and is it safe?

Rapid Micro Biosystems Inc. (Class A) (RPID) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: RPID RQD Cockpit RPID 12M Forecast RPID Earnings & Move RPID Dividends & DRIP RPID Insiders & 13F RPID Whale Options RPID Profit Sankey RPID News & Why